Abbott announced that its FreeStyle Libre 2 integrated continuous glucose monitoring system (iCGM) received FDA 510(k) clearance for use in children ages four and older. The system consists of a next-generation self-applied sensor applied to the back of the upper arm. It is about the size of two-stacked quarters and removes the requirement of fingersticks for testing glucose levels.
“Using this technology can improve time in optimal glucose range and lower HbA1c because we can get a full picture of what a child’s glucose levels are doing without having to disrupt their play or sleep with painful fingersticks. The alarms are a bonus because they provide parents a level of reassurance.” – Larry Kurt Midyett, M.D., pediatric endocrinologist, Midwest Women’s and Children’s Specialty Group
The system transmits glucose every minute and has optional real-time alarms that notify a patient when glucose levels are too low or high without scanning (enabled via the use of Bluetooth technology). Abbott touts the technology as the first and only iCGM system that has sustainable performance for up to 14 days.
Related Articles
-
The guidance seeks to balance the need to obtain data on the safety and effectiveness of drugs, biological products and medical devices in the pediatric population with risks associated with exposure to such products and the reality that children cannot…
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
